English Journal

CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value.

Pardanani A1, Reichard KK2, Zblewski D1, Abdelrahman RA1, Wassie EA1, Morice Ii WG2, Brooks C3, Grogg KL2, Hanson CA2, Tefferi A1, Chen D2.
Leukemia.Leukemia.2015 Dec 18. doi: 10.1038/leu.2015.348. [Epub ahead of print]
CD123 is the α-subunit of the interleukin-3 receptor; it represents a potential therapeutic target in systemic mastocytosis (SM) given its absent expression on normal/reactive mast cells (MCs) and aberrant expression on neoplastic MCs. We studied 58 SM patients to define CD123 expression patterns b
PMID 26678095

Del(20q) in patients with chronic lymphocytic leukemia: a therapy-related abnormality involving lymphoid or myeloid cells.

Yin CC1, Tang G1, Lu G1, Feng X1, Keating MJ2, Medeiros LJ1, Abruzzo LV1.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.Mod Pathol.2015 Aug;28(8):1130-7. doi: 10.1038/modpathol.2015.58. Epub 2015 May 8.
Deletion 20q (Del(20q)), a common cytogenetic abnormality in myeloid neoplasms, is rare in chronic lymphocytic leukemia. We report 64 patients with chronic lymphocytic leukemia and del(20q), as the sole abnormality in 40, a stemline abnormality in 21, and a secondary abnormality in 3 cases. Fluoresc
PMID 25953391

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators.
The Lancet. Oncology.Lancet Oncol.2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18.
BACKGROUND: VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1 monoclonal antibody and VEGF receptor-2 antagonist. We aimed to assess the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma followi
PMID 26095784

Japanese Journal

Dic (17;20) (p11;q11) Preceded MLL Gene Amplification in a Patient with de novo Mixed-Lineage Leukemia

AMAKAWA Ryuichi,HIRAMOTO Nobuhiro,KAWANO Seiji,HYO Akira,NAKAMICHI Naoto,TAJIMA Kenichiro,ITO Tomoki,MORI Shinichiro,KISHIMOTO Yuji,FUKUHARA Shirou
Journal of clinical and experimental hematopathology 50(1), 51-58, 2010-05-01
… Add (11q23) abnormality was found in sideline karyotypes as well as the stemline abnormality of dic(17;20) (p11;q11). …
NAID 10026388075